

Resource Summary Report

Generated by [RRID](#) on Sep 6, 2026

Caov-4

RRID:CVCL_0202

Type: Cell Line

Proper Citation

RRID:CVCL_0202

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0202

Proper Citation: RRID:CVCL_0202

Description: Cell line Caov-4 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: High grade ovarian serous adenocarcinoma

Defining Citation: [PMID:3518877](#), [PMID:6935474](#), [PMID:9698466](#), [PMID:20164919](#), [PMID:20204287](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:23839242](#), [PMID:25230021](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:27235858](#), [PMID:27397505](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31395879](#), [PMID:35839778](#)

Comments: Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: TCGA-110-CL cell line panel., Part of: OCCP ovarian cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Caov-4

Synonyms: CaOv-4, CaOV-4, CAOv-4, CAOv4, Caov4

Cross References: CLO:CLO_0002196, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:HTB-76, BioGRID_ORCS_Cell_line:843, BioSample:SAMN03472755, BioSample:SAMN03472784, BioSample:SAMN10987815, cancercellines:CVCL_0202, CancerTools:161927, CCRID:1101HUM-PUMC000367, Cell_Model_Passport:SIDM00918, ChEMBL-

Cells:CHEMBL3308232, ChEMBL-Targets:CHEMBL2366249, Cosmic:688093, Cosmic:809112, Cosmic:844350, Cosmic:849610, Cosmic:948287, Cosmic:949090, Cosmic:949226, Cosmic:1305321, Cosmic-CLP:949090, DepMap:ACH-000103, EGA:EGAS00001000978, GDSC:949090, GEO:GSM784562, GEO:GSM886919, GEO:GSM887985, GEO:GSM1001487, GEO:GSM1291131, GEO:GSM1669662, IARC_TP53:1414, IARC_TP53:28484, IARC_TP53:30198, IGRhCellID:Caov4, IZSLER:BS TCL 183, KCLB:30076, LiGeA:CCLE_173, LINCS_LDP:LCL-1520, NCBI_Iran:C595, Pharmacodb:Caov4_183_2019, PRIDE:PXD030304, Progenetix:CVCL_0202, PubChem_Cell_line:CVCL_0202, Wikidata:Q54808586

ID: CVCL_0202

Record Creation Time: 20220427T215440+0000

Record Last Update: 20260905T174517+0000

Ratings and Alerts

No rating or validation information has been found for Caov-4.

No alerts have been found for Caov-4.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Zhang Z, et al. (2026) A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy. *Cell*, 189(10), 2898.

Lujano-Olazaba O, et al. (2026) RelB drives integrin-mediated stress tolerance and relapse in high-grade serous ovarian cancer. *Cell reports*, 45(7), 117650.

Waters JA, et al. (2025) Preadipocyte-induced upregulation of IGFBP5 enhances ovarian cancer tumorigenesis via CREB signaling. *iScience*, 28(8), 113034.

Nelson BE, et al. (2025) Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(18), 3864.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. *Cell chemical biology*, 31(7), 1247.